Estimation of the possible economic effects of a sequential testing strategy with NT-ProBNP before echocardiography in primary care

Clinical Laboratory

Volumn 60, Issue 6, 2014, Pages 881-886

  Khezri, Banafsheh Seyyed ^a   Helmersson Karlqvist, Johanna ^a   Larsson, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cost; Echocardiography; Health economics; Heart failure; Laboratory test; NT proBNP; Primary care

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEART FAILURE; HUMAN; MALE; PRIMARY MEDICAL CARE; PROTEIN BLOOD LEVEL; SEQUENTIAL TESTING STRATEGY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD CHEMICAL ANALYSIS; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRIMARY HEALTH CARE; SWEDEN;

EID: 84903788502     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.130613     Document Type: Article

References (21)

1. Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515-23.
2. Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden 1988 to 2004. Circ Cardiovasc Qual Outcomes 2010;3:573-80.
3. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006;11:95-107. (Pubitemid 44288725)
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. (Developed in collaboration with the Heart Failure Association HFA) of the ESC. Eur Heart J 2012;33:1787-847.
5. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011;124:2865-73.
6. Marwick TH, Raman SV, Carrio I, Bax JJ. Recent developments in heart failure imaging. JACC Cardiovasc Imaging 2010;3:429-39.
7. Paterson DI, OMeara E, Chow BJ, Ukkonen H, Beanlands RS. Recent advances in cardiac imaging for patients with heart failure. Curr Opin Cardiol 2011;26:132-43.
8. Adlbrecht C, Hülsmann M, Neuhold S, Strunk G, Pacher R. Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure. J Heart Lung Transplant 2013;32:533-8.
9. Bielecka-Dabrowa A, von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M. Heart failure biomarkers in patients with dilated cardiomyopathy. Int J Cardiol 2013;doi:pii: S0167-5273(13)00199-X. 10.1016/j.ijcard.2013.01.157.
10. Ferrandis MJ, Ryden I, Lindahl TL, Larsson A. Ruling out cardiac failure: Cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography. Ups J Med 2013;Sci 118:75-9.
11. Gallagher MJ, McCullough PA. The emerging role of natriuretic peptides in the diagnosis and treatment of decompensated heart failure. Curr Heart Fail Rep 2004;1:129-35.
12. McCullough PA. B-type natriuretic peptide and its clinical implications in heart failure. Am Heart Hosp J 2004;2:26-33.
13. Vanderheyden M, Vrints C, Verstreken S, Bartunek J, Beunk J, Goethals M. B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications. Biomark Med 2010;4:315-20.
14. Federico C. Natriuretic Peptide system and cardiovascular disease. Heart Views 2010;11:10-5.
15. Maisel A, Mueller C, Adams K Jr, Anker SD, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39.
16. McIntyre HF. Leveraging guidelines: understanding heart failure, organizing care. Commentary on the 2010 NICE chronic heart failure guideline update. Eur J Heart Fail 2011;13:14-7.
17. Manzano L, Escobar C, Cleland JG, Flather M. Diagnosis of elderly patients with heart failure. Eur J Heart Fail 2012;14:1097-103.
18. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220.
19. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7. (Pubitemid 43100029)
20. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881-9.
21. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358(20):2107-16. (Pubitemid 351679597)